Bortezomib in combination with intermediate‐dose dexamethasone and continuous low‐dose oral cyclophosphamide for relapsed multiple myeloma

Kropff, Martin; Bisping, Guido; Schuck, Elke; Liebisch, Peter; Lang, Nicola; Hentrich, M.; Dechow, Tobias; Kröger, Nicolaus; Salwender, Hans; Metzner, Bernd; Sezer, Orhan; Engelhardt, Monika; Wolf, Hans‐Heinrich; Einsele, Hermann; Volpert, Sarah; Heinecke, Achim; E. Berdel, Wolfgang; Kienast, Joachim; behalf of the Deutsche Studiengruppe Multiples Myelom, DSMM, on

doi:10.1111/j.1365-2141.2007.06656.x

Public

Bortezomib in combination with intermediate‐dose dexamethasone and continuous low‐dose oral cyclophosphamide for relapsed multiple myeloma

Published in British Journal of Haematology • Jul 3, 2007

Authors:

Martin Kropff

Guido Bisping

Elke Schuck

Abstract

A phase 2 trial was performed to study the combination of bortezomib (VELCADE) with intermediate-dose dexamethasone (DEX), and continuous low-dose oral cyclophosphamide (CY) in patients with relapsed multiple myeloma (MM). Fifty-four patients with advanced MM were enroled to receive eight 3-week tre...

Subject

Bortezomib

Medicine

Dexamethasone

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!